NO20050018L - Lasofoxifentabletter og belegg - Google Patents

Lasofoxifentabletter og belegg

Info

Publication number
NO20050018L
NO20050018L NO20050018A NO20050018A NO20050018L NO 20050018 L NO20050018 L NO 20050018L NO 20050018 A NO20050018 A NO 20050018A NO 20050018 A NO20050018 A NO 20050018A NO 20050018 L NO20050018 L NO 20050018L
Authority
NO
Norway
Prior art keywords
lasofoxifene
tablets
coatings
active ingredient
triacetin
Prior art date
Application number
NO20050018A
Other languages
English (en)
Inventor
Daniel Scott Gierer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20050018L publication Critical patent/NO20050018L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er beskrevet farmasøytiske preparater hvor lasofoxifen benyttes som en aktiv ingrediens, som har ensartet legemiddelfordeling og styrke og som inneholder et silisiumdioksyd for å redusere tap av den aktive ingrediens under fremstillingsprosessen, og metoder for fremstilling av slike preparater. Triacetin som plastiseringsmiddel i overtrekk, ble vist å gi god stabilitet for lasofoxifen.
NO20050018A 2002-07-10 2005-01-03 Lasofoxifentabletter og belegg NO20050018L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39509002P 2002-07-10 2002-07-10
PCT/IB2003/003074 WO2004006895A1 (en) 2002-07-10 2003-06-30 Lasofoxifene tablet and its coating

Publications (1)

Publication Number Publication Date
NO20050018L true NO20050018L (no) 2005-01-12

Family

ID=30115812

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050018A NO20050018L (no) 2002-07-10 2005-01-03 Lasofoxifentabletter og belegg

Country Status (36)

Country Link
US (2) US20040057992A1 (no)
EP (1) EP1534248B1 (no)
JP (2) JP4446446B2 (no)
KR (1) KR100782693B1 (no)
CN (1) CN100344278C (no)
AP (1) AP2005003201A0 (no)
AR (1) AR040434A1 (no)
AT (1) ATE550017T1 (no)
AU (1) AU2003247017B2 (no)
BR (1) BR0312563A (no)
CA (1) CA2489407C (no)
CY (1) CY1112892T1 (no)
DK (1) DK1534248T3 (no)
EA (1) EA007268B1 (no)
EC (1) ECSP055528A (no)
ES (1) ES2395123T3 (no)
HK (1) HK1077747A1 (no)
HN (1) HN2003000206A (no)
HR (1) HRP20041196A2 (no)
IL (2) IL165746A0 (no)
IS (1) IS7594A (no)
MA (1) MA27318A1 (no)
MX (1) MXPA05000394A (no)
NO (1) NO20050018L (no)
NZ (1) NZ537278A (no)
OA (1) OA12883A (no)
PA (1) PA8576201A1 (no)
PE (1) PE20040104A1 (no)
PL (1) PL374913A1 (no)
PT (1) PT1534248E (no)
SI (1) SI1534248T1 (no)
TN (1) TNSN05006A1 (no)
TW (1) TW200406222A (no)
UY (1) UY27886A1 (no)
WO (1) WO2004006895A1 (no)
ZA (1) ZA200410196B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2006105806A1 (en) * 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
EP1878426B1 (en) * 2005-04-26 2010-06-16 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation containing biguanide compound
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
SG183059A1 (en) 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
CA2587805C (en) * 2007-04-25 2014-02-18 The Procter & Gamble Company Improved vitamin d content uniformity in pharmaceutical dosage forms
MY164765A (en) * 2007-10-10 2018-01-30 Avantor Performance Mat Llc Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
WO2009135067A1 (en) * 2008-05-01 2009-11-05 Wyeth Pharmaceutical polish formulations
KR101659971B1 (ko) * 2008-05-02 2016-09-26 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
PT2451445T (pt) * 2009-07-06 2019-07-10 Boehringer Ingelheim Int Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
CA2851862C (en) * 2011-10-17 2020-04-14 Lexicon Pharmaceutical Inc. Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
EP2851075B1 (en) 2012-05-14 2021-12-01 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative
US20160220494A1 (en) * 2013-09-13 2016-08-04 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
RU2539375C1 (ru) * 2013-11-07 2015-01-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) * 2014-03-14 2014-06-04 *** 一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
US20190183850A1 (en) * 2016-07-25 2019-06-20 Canopy Growth Corporation New cannabis tablet formulations and compositions and methods of making the same
DK3525774T3 (da) 2016-10-11 2022-03-14 Univ Duke Lasofoxifen behandling af er+ brystcancer
CN112261937B (zh) 2018-04-10 2023-11-14 杜克大学 乳腺癌的拉索昔芬治疗
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN114288258A (zh) * 2022-02-18 2022-04-08 山东新时代药业有限公司 一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182A (en) * 1845-09-09 Island
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6372457B1 (en) 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
KR200161927Y1 (ko) * 1997-08-26 1999-12-01 윤종용 냉장고
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (en) * 2000-03-10 2001-11-14 Pfizer Products Inc. Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
NZ528886A (en) * 2001-05-01 2005-04-29 Pfizer Prod Inc A dry process for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Also Published As

Publication number Publication date
CA2489407A1 (en) 2004-01-22
BR0312563A (pt) 2005-04-19
HN2003000206A (es) 2004-07-27
HK1077747A1 (en) 2006-02-24
CY1112892T1 (el) 2016-04-13
ES2395123T3 (es) 2013-02-08
JP2005535671A (ja) 2005-11-24
US20070110800A1 (en) 2007-05-17
HRP20041196A2 (en) 2005-04-30
AU2003247017B2 (en) 2008-03-06
IL165746A (en) 2008-12-29
SI1534248T1 (sl) 2012-07-31
AU2003247017A1 (en) 2004-02-02
KR100782693B1 (ko) 2007-12-07
PL374913A1 (en) 2005-11-14
AP2005003201A0 (en) 2005-03-31
ZA200410196B (en) 2006-07-26
TW200406222A (en) 2004-05-01
DK1534248T3 (da) 2012-06-25
EA200401583A1 (ru) 2005-06-30
CA2489407C (en) 2009-01-27
US20040057992A1 (en) 2004-03-25
JP2007031451A (ja) 2007-02-08
AR040434A1 (es) 2005-04-06
JP4446446B2 (ja) 2010-04-07
US7553500B2 (en) 2009-06-30
PE20040104A1 (es) 2004-02-27
WO2004006895A1 (en) 2004-01-22
PT1534248E (pt) 2012-05-25
OA12883A (en) 2006-09-15
ECSP055528A (es) 2005-03-10
PA8576201A1 (es) 2004-05-26
IL165746A0 (en) 2006-01-15
ATE550017T1 (de) 2012-04-15
TNSN05006A1 (fr) 2007-05-14
EA007268B1 (ru) 2006-08-25
EP1534248B1 (en) 2012-03-21
MXPA05000394A (es) 2005-03-23
CN1668285A (zh) 2005-09-14
IS7594A (is) 2004-12-13
KR20050017102A (ko) 2005-02-21
MA27318A1 (fr) 2005-05-02
CN100344278C (zh) 2007-10-24
NZ537278A (en) 2007-07-27
EP1534248A1 (en) 2005-06-01
UY27886A1 (es) 2004-02-27

Similar Documents

Publication Publication Date Title
NO20050018L (no) Lasofoxifentabletter og belegg
TW200745111A (en) New compounds
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
NO20062884L (no) AKT-proteinkinaseinhibitorer
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
TW200621762A (en) Novel compounds
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
WO2001087839A8 (en) Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NO20070570L (no) Forbindelser.
UA90285C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
TW200606164A (en) New compounds
DE602004011966D1 (en) Heterocyclylverbindungen
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
NO20020282L (no) Nytt difenyl-piperidinderivat
TW200800984A (en) New compounds
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
IL151359A0 (en) Esmolol formulation
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
NO20083441L (no) Benzoisoindolderivater for behandling av smerte
WO2004106307A3 (fr) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
WO2004056808A8 (en) Novel piperidine derivatives as modulators of chemokine receptor ccr5
WO2004056809A8 (en) Novel piperidine derivatives as modulators of chemokine receptor ccr5
WO2005034954A3 (en) Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application